The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often come with side effects such as nausea.

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose medical interventions for weight management. Some critics argue that using the drugs is akin to "taking a shortcut," overlooking the complex factors that contribute to obesity.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau,

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.

Britain's Terry Smith made public for the first time on Thursday why his fund dumped its Diageo stake last year, citing problems with its new management and early signs that weight loss drugs threatened the drinks sector.

Everything you need to know about using Ozempic, Wegovy, and Mounjaro to shed those extra pounds. We dive into their perks, potential pitfalls, and why you should always have a doc on board.